The company has been formed to develop and commercialise therapies for retinal dystrophies – degenerative conditions that affect vision.
£12m investment to develop gene therapies for cause of blindness
- 30 January 2014
- Research
- Innovation
Nightstar, a new spin-out company from the University of Oxford and its research commercialisation company Isis Innovation, is to receive a £12 million investment from Syncona, an independent subsidiary of the Wellcome Trust.